The hereditary abnormalities and genetic therapy of BCM

Abstract

Blue cone monochromia is a visual disorder caused by genetic mutation, which is a single gene genetic disease thus very suitable for gene therapy. With this technique, mutations in patients' opsin genes can be repaired, thereby restoring their visual recognition of red and green. Compared with traditional treatment methods, gene therapy has obvious advantages in improving curative effect and is expected to achieve a radical cure of the disease. However, gene therapy still faces some challenges and limitations, such as technical validation, cost and accessibility issues. This review focuses on the progress of gene diagnosis and treatment technology in recent years and its application to blue cone monochromatic diseases. Further research and clinical practice will show more support and validation for the development of this treatment, thus providing patients with better treatment options.